Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant
Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant
复制标题
DOI：
10.1016/j.xcrm.2020.100099
复制
发表时间：
2020-09-22
影响因子：
14.3
通讯作者：
Gupta, Ravindra K.
中科院分区：
文献类型：
--
作者：
Mlcochova, Petra;Collier, Dami;Gupta, Ravindra K.
在医院快速诊断COVID-19是必不可少的，尽管这是复杂的30%-50%的鼻/喉拭子是阴性的SARS-CoV-2核酸扩增检测（NAAT）。此外，D 614 G刺突突变体在大流行中占主导地位，目前还不清楚设计用于检测抗刺突抗体的血清学试验如何针对该变体进行。我们评估了联合快速抗体床旁检测（POC）和核酸检测对由野生型或D 614 G刺突突变型SARS-CoV-2引起的疑似COVID-19疾病的诊断准确性。仅通过快速NAAT，COVID-19的总体检出率为79.2%（95%CI 57.8-92.9）。联合床旁抗体检测和快速NAAT不受D 614 G的影响，对COVID-19诊断具有非常高的灵敏度和非常高的特异性。
Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%-50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wildtype or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95% CI 57.8-92.9) by rapid NAAT alone. The combined point of care antibody test and rapid NAAT is not affected by D614G and results in very high sensitivity for COVID-19 diagnosis with very high specificity.